The hepatitis C drugs market size is expected to reach US$ 11.39 billion by 2030, from US$ 8.60 billion in 2023, growing at a CAGR of 4.1% during the forecast period. Hepatitis C is a viral infection that causes liver swelling, called inflammation. Hepatitis C can lead to serious liver damage. The hepatitis C virus (HCV) spreads through contact with blood that has the virus in it.
Symptoms of hepatitis C include fever, feeling very tired, loss of appetite, nausea and vomiting, abdominal pain, dark urine, pale feces, joint pain, and jaundice (yellowing of the skin or eyes).
Hepatitis c Drugs Market Regional Insights:
Figure 1. Global Hepatitis C Drugs Market Share (%), by Region, 2023
To learn more about this report, request sample copy
Analysts’ Views on Global Hepatitis C Drugs Market:
Hepatitis C drugs market is expected to propel over the forecast period due to the increasing prevalence of hepatitis c globally and increasing research and development, and product launches by the market players. Moreover, increasing funding for research and developmental activities is also expected to boost the market growth over the forecast period.
Hepatitis C Drugs Market Drivers:
Hepatitis c drugs market Opportunities:
Hepatitis C Drugs Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 8.60 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 4.1% | 2030 Value Projection: | US$ 11.39 Bn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Gilead Sciences, AbbVie, Merck & Co, Bristol-Myers Squibb, Johnson & Johnson, F. Hoffmann-La Roche AG, Boehringer Ingelheim, and Achillion Pharmaceuticals |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Hepatitis C Drugs Market Trends:
Hepatitis C drugs market Restraints:
Market players should focus on the adverse effects causing due to consumption of the drugs products, and work towards minimizing the adverse effects which aid in the market growth over the forecast period.
Recent Developments:
New product launches:
Acquisition and partnerships:
Figure 2. Global Hepatitis C drugs market Share (%), by Route of Administration, 2023
To learn more about this report, request sample copy
Top Companies in Hepatitis C drugs market:
Definition: Hepatitis C is a viral infection that causes liver swelling, called inflammation. Hepatitis C can lead to serious liver damage. The hepatitis C virus (HCV) spreads through contact with blood that has the virus in it.
Few Other Promising Reports in Pharmaceuticals
Share
About Author
Ghanshyam Shrivastava
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients